Grace Therapeutics (GRCE) Non-Current Deferred Tax Liability (2022 - 2026)

Grace Therapeutics has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $612000.0 in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 73.53% year-over-year to $612000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $612000.0 (down 73.53% YoY) and the FY2026 annual result came in at $612000.0, down 73.53% from the prior year.
• Non-Current Deferred Tax Liability fell to $612000.0 in Q1 2026 per GRCE's latest filing, from $2.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $16.9 million in Q1 2022 and troughed at $612000.0 in Q1 2026.
• A 5-year average of $7.1 million and a median of $5.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2024 and 2026: Non-Current Deferred Tax Liability decreased 24.95% in 2024, then tumbled 73.53% in 2026.
• Over 5 years, Non-Current Deferred Tax Liability stood at $16.2 million in 2022, then sank by 60.52% to $6.4 million in 2023, then slumped by 47.95% to $3.3 million in 2024, then tumbled by 30.63% to $2.3 million in 2025, then sank by 73.53% to $612000.0 in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $612000.0, $2.3 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.